Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amicus Therapeutics (NQ: FOLD ) 10.35 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Amicus Therapeutics < Previous 1 2 3 Next > Short Volatility Alert: Amicus Therapeutics, Inc. June 22, 2022 On Tuesday, shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) experienced volatile short activity. After the activity, the stock price went up +5.67% to $9.88. The overall... Via Benzinga Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates May 31, 2022 May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... Via Benzinga The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine May 11, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Amicus Shares Encouraging Long-Term Data Of AT-GAA Study In Pompe Disease March 16, 2022 Amicus Therapeutics Inc (NASDAQ: FOLD) has Via Benzinga 7 Biotech Stocks With Key Catalysts for May May 11, 2022 The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. Via InvestorPlace FDA Extends Review Of Amicus Therapeutics' AT-GAA For The Treatment Of Pompe Disease By Three Months May 10, 2022 The U.S. Via Benzinga Recap: Amicus Therapeutics Q1 Earnings May 09, 2022 Amicus Therapeutics (NASDAQ:FOLD) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga Earnings Outlook For Amicus Therapeutics May 06, 2022 Amicus Therapeutics (NASDAQ:FOLD) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Amicus... Via Benzinga Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates May 01, 2022 The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a... Via Benzinga Amicus Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know April 27, 2022 Amicus Therapeutics (NASDAQ:FOLD) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. Via Benzinga Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall February 24, 2022 Amicus Therapeutics Inc (NASDAQ: FOLD) has terminated its plans to spin off its gene therapy assets, citing 'existing market conditions.' With "market... Via Benzinga The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company February 24, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... Via Benzinga Amicus Therapeutics Earnings Preview February 23, 2022 Amicus Therapeutics (NASDAQ:FOLD) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 14, 2022 January 14, 2022 Upgrades According to Seaport Global, the prior rating for Lennar Corp (NYSE: Via Benzinga 10 Biggest Price Target Changes For Friday January 14, 2022 Keybanc cut Robinhood Markets, Inc. (NASDAQ:HOOD... Via Benzinga 60 Biggest Movers From Yesterday January 11, 2022 Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company... Via Benzinga Mid-Afternoon Market Update: Dow Tumbles 250 Points; Zynga Shares Spike Higher January 10, 2022 Toward the end of trading Monday, the Dow traded down 0.70% to 35,978 while the NASDAQ fell 0.93% to 14,796.51. The S&P also fell, dropping, 0.72% to 4,643.29. The U.S.... Via Benzinga Mid-Day Market Update: Nasdaq Dips 300 Points; Apria Shares Surge January 10, 2022 Midway through trading Monday, the Dow traded down 1.23% to 35,787.07 while the NASDAQ fell 2.07% to 14,627.21. The S&P also fell, dropping, 1.52% to 4,605.95. The U.S. has... Via Benzinga 45 Stocks Moving In Monday's Mid-Day Session January 10, 2022 Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ: ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired... Via Benzinga Amicus Therapeutics, inc (FOLD) Q3 2021 Earnings Call Transcript November 09, 2021 FOLD earnings call for the period ending September 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021 November 15, 2021 Upgrades For Targa Resources Corp (NYSE: Via Benzinga The Week In SPAC News - Sunday, Oct. 3 October 03, 2021 In SPAC news this week, Amicus Therapeutics announced its intent to sell its gene therapy unit to ARYA Sciences Acquisition Corp IV, a SPAC sponsored by Perceptive Advisors. Via Talk Markets Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business September 29, 2021 Amicus Therapeutics Inc (NASDAQ: FOLD) has agreed to spin off its gene therapy business to Sciences Acquisition Corp IV (NASDAQ: ARYD) and launch genetic... Via Benzinga The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data November 09, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... Via Benzinga Why Are Amicus Therapeutics Shares Trading Higher Today? September 29, 2021 The FDA has accepted for review Amicus Therapeutics Inc's (NASDAQ: FOLD) Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug... Via Benzinga Exposures Product Safety Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 September 30, 2021 Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session September 29, 2021 Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $32.6... Via Benzinga The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug September 29, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Tuesday's After-Market Session September 07, 2021 Gainers Cellectar Biosciences (NASDAQ:CLRB Via Benzinga Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021? August 12, 2021 One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail. Via The Motley Fool < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.